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Deficiencies in protein degradation and proteolytic
function within neurons are linked to a number of neuro-
degenerative diseases and developmental disorders.
Compartmentalized cultures of peripheral neurons were
used to investigate the properties and relative abun-
dance of the proteolytic machinery in the axons and cell
bodies of sympathetic and sensory neurons. Immuno-
blotting of axonal proteins demonstrated that LAMP2,
LC3, and PSMA2 were abundant in axons, suggesting
that lysosomes, autophagosomes and proteasomes
were located in axons. Interestingly, the expression of
proteins associated with lysosomes and proteasomes
were upregulated selectively in axons by NGF stimula-
tion of the distal axons of sympathetic neurons, suggest-
ing that axonal growth and maintenance requires local
protein turnover. The regulation of the abundance of
both proteasomes and lysosomes in axons by NGF
provides a link between protein degradation and the
trophic status of peripheral neurons. Inhibition of protea-
somes located in axons resulted in an accumulation of
ubiquitinated proteins in these axons. In contrast, lyso-
some inhibition in axons did not result in an accumulation
of ubiquitinated proteins or the transferrin receptor,
a transmembrane protein degraded by lysosomes. Inter-
estingly, lysosomes were transported both retrogradely
and anterogradely, so it is likely that ubiquitinated
proteins that are normally destined for degradation
by lysosomes in axons can be transported to the
cell bodies for degradation. In summary, proteasomal
degradation occurs locally, whereas proteins degraded
by lysosomes can most likely either be degraded
locally in axons or be transported to cell bodies for
degradation. VC 2012 Wiley Periodicals, Inc.
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Protein degradation is a process common to all cell
types and is important in both cell maintenance and dis-
ease (Klionsky and Emr, 2000; Luzio et al., 2007; Tai
and Schuman, 2008). Protein degradation is involved in
growth cone sprouting and cytoskeletal remodeling
(Verma et al., 2005), receptor turnover (Colledge et al.,
2003; Arancibia-Carcamo et al., 2009), and elimination
of misfolded proteins (Goldberg, 2003). Degradation
occurs by three mechanisms: ubiquitin-proteasome deg-
radation, endosomal-lysosomal degradation, and autoph-
agy-lysosome degradation. The ubiquitin-proteasome
system degrades cytosolic proteins that have been
targeted for proteolysis by the addition of chains of four
or more ubiquitin molecules (Thrower et al., 2000).
Proteolysis occurs in the proteosome, a protein complex
that identifies polyubiquitin chains and cleaves the target
protein into small groups of amino acids (Voges et al.,
1999). In contrast, monoubiquitination events target
proteins to the endosomal-lysosomal degradation system.
Transmembrane proteins typically are internalized after
addition of monoubiquitin, often on several lysines, and
are ultimately degraded by lysosomal enzymes after
endosomes fuse with lysosomes (Chau et al., 1989;
Hicke, 2001; Luzio et al., 2007). The autophagy-lyso-
some system functions in large-scale degradation events,
resulting in targeted degradation of protein aggregates or
entire organelles that have been ubiquitinated and linked
to p62/SQSTM1 (Pankiv et al., 2007; Kim et al., 2008;
Mizushima et al., 2008; Yang and Klionsky, 2009).
Recruitment into autophagic vesicles is mediated by
interaction between p62/SQSTM1 and the microtubule-
associated protein LC3, a marker for autophagy that is
involved in autophagic membrane formation (Kuma
et al., 2007; Pankiv et al., 2007).
Defects in protein degradation have been implicated
in a variety of neurodegenerative disorders, including
Parkinson’s disease, Alzheimer’s disease, Huntington’s dis-
ease, and amyotrophic lateral sclerosis (Taylor et al., 2002;
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Rubinsztein, 2006). However, it is not fully understood
how defects in protein degradation cause, or develop
from, neurodegenerative diseases. Furthermore, the extent
to which the protein degradation machinery is localized
within axons of large, peripheral neurons is not explicitly
known, nor do we know how they contribute to global
cellular protein turnover. Although there is evidence for
the localization of protein degradation machinery within
cell somas and dendrites (Colledge et al., 2003; Arancibia-
Carcamo et al., 2009; Lee et al., 2011), it is not clear how
this machinery localizes and carries out its functions within
axons (Overly et al., 1996; Korhonen and Lindholm,
2004; Song et al., 2008).
We utilized compartmentalized cultures of periph-
eral neurons to ascertain the abundance and regulation of
the proteolytic machinery in axons compared with cell
bodies. Protein components of lysosomes, autophago-
somes, and proteasomes were all located in axons and lyso-
somes, and proteasomes were upregulated in response to
nerve growth factor (NGF) stimulation. Inhibition of axo-
nal proteasomes resulted in an accumulation of ubiquiti-
nated proteins in axons. However, inhibition of axonal
lysosomes did not result in an accumulation of ubiquiti-
nated proteins, suggesting that proteasomal degradation
occurs locally, whereas proteins degraded by lysosomes
can be transported to cell bodies for degradation.
MATERIALS AND METHODS
Sympathetic Neuron Cultures
Superior cervical ganglion (SCG) neurons were obtained
from P0 Sprague-Dawley rats (Charles River, Portage, MI;
Goslin and Banker, 1998; Tsui-Pierchala et al., 2002).
Neurons were plated on gas–plasma-treated substrates (Harrick
Plasma, Ithaca, NY) coated with type I collagen (BD Bio-
sciences, San Jose, CA). Neurons were plated in one of three
formats: as mass cultures in the center of 35-mm2 dishes, as
droplets in the center of 22 3 22 mm No. 1.5 coverslips for
fluorescence imaging, or as compartmentalized ‘‘Campenot’’
chambers (Tyler Research, Edmonton, Alberta, Canada; Tsui-
Pierchala and Ginty, 1999; Campenot et al., 2009). SCG neu-
rons were maintained in minimal essential medium (MEM)
containing 50 ng/ml NGF, 10% fetal bovine serum (FBS), the
antimitotic agents aphidicolin and flourodeoxyuridine (Sigma,
St. Louis, MO), and penicillin–streptomycin–glutamine sup-
plement (Invitrogen, Carlsbad, CA). Procedures involving ani-
mals were in accordance with the University Committee on
Use and Care of Animals (UCUCA) and the Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC).
NGF Withdrawal and Reintroduction
Sympathetic neurons were maintained for 21 days to
allow an NGF-independent, adult phenotype to develop
(Goedert et al., 1978; Easton et al., 1997; Orike et al., 2001).
To test the effects of NGF on expression of proteins associated
with the proteolytic machinery, neurons in compartmentalized
cultures were deprived of NGF for 48 hr on both their
cell bodies and their axons (see Fig. 3A), a period of time
sufficient to extinguish NGF signaling (unpublished observa-
tions). After NGF withdrawal, cultures were stimulated either
with NGF (50 ng/ml) or with medium alone for 4 or 48 hr.
Cellular lysates were then collected from the cell body and
terminal compartments.
Monitoring Protein Degradation
Inhibition of protein degradation was achieved by selec-
tively inhibiting proteasomes using 5 lM epoxomicin (Biomol
Research Laboratories, Plymouth Meeting, PA), lysosomes
using 1 lM concanamycin A (Biomol Research Laboratories),
and autophagy using 10 mM 3-methyl-adenine (3-MeA;
Sigma). All inhibitors were used at doses similar to those sug-
gested by the manufacturer and in other published reports for
inhibition of the various pathways with minimal acute toxic-
ity. After 24 hr of inhibition, lysates were collected separately
from the cell body and terminal compartments and examined
for the accumulation of ubiquitinated proteins. Mass cultures
of SCG neurons were exposed to inhibitors for up to 96 hr to
observe their effects on cell viability. Phase-contrast images
were collected using a Zeiss Axiovert inverted microscope
equipped with a 310 objective (Zeiss, Jena, Germany).
Immunocytochemisty and Microscopy
SCG cultures were fixed for 10 min in 4% paraformal-
dehyde buffered with phosphate-buffered saline (PBS), perme-
abilized for 5 min in 0.1% Triton X-100 in PBS, and blocked
for 1 hr in 4% bovine serum albumin (BSA), with shaking.
Samples were incubated overnight with a rabbit antiprotea-
some subunits antibody (1:500 dilution; Invitrogen) on a
rotary shaker at 48C and were then incubated for 2 hr with
Alexa-488 goat anti-rabbit secondary antibody (1:1,000 dilu-
tion; Invitrogen) with shaking and counterstained for 30 min
with Alexa-568 phalloidin (1:200 dilution; Invitrogen). Con-
focal imaging was performed using an SP5 inverted confocal
microscope equipped with a resonance scanner and a 360
glycerol immersion objective (Leica, Wetzlar, Germany).
Lysosomes were labeled using the fluorescent dye LysoTracker
Yellow HCK-123 (Invitrogen). Live SCG cultures were incu-
bated for 45 min in culture medium containing LysoTracker
and were then imaged in resonance scan mode (16,000 HZ)
within a humidified culture chamber maintained at 378C, 5%
CO2 (TokaiHit, Shizuoka-ken, Japan). Images were collected
as single optical sections, with fluorescence and phase-contrast
images acquired simultaneously every 2 sec to track lysosome
movement. Nocodazole was applied for 30 min after each
initial imaging session, and additional images were collected to
demonstrate the importance of microtubules for lysosome
transport.
Immunoblotting
It was not possible to obtain sufficient amounts of pro-
tein to assay the biochemical activity of protein degradation
systems in axons. Therefore, immunoblots were used to assess
the relative abundance of proteins involved in protein degra-
dation. Protein extracts were loaded onto 4–20% Tris-glycine
gradient minigels for SDS-PAGE and were transferred to a
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PVDF membrane (Millipore, Billerica, MA). Membranes were
rinsed in TBST (10 mM Tris, pH 7.4, 100 mM sodium
chloride, 0.1% Tween 20) and blocked for 1 hr in TBST con-
taining 2% BSA. Membranes were then incubated for 3 hr in
the primary antibody diluted in 2% BSA-TBST at room tem-
perature or overnight at 48C. Horseradish peroxidase (HRP)-
conjugated secondary antibodies (Jackson Immunoresearch,
West Grove, PA), diluted in 2% BSA-TBST, were used for
detection along with a chemiluminescent substrate (Thermo
Scientific, Waltham, MA). The following primary antibodies
were used: rabbit anti-PSMA2 (1:1,000 dilution; Cell Signal-
ing, Danvers, MA), rabbit anti-LAMP2 (1:2,000 dilution;
Invitrogen), rabbit anti-LC3B (1:1,000 dilution; Cell Signal-
ing), mouse anti-transferrin receptor (1:500 dilution; Invitro-
gen), rabbit antitotal ubiquitin (1:200 dilution; Sigma), rabbit
anti-beclin (1:1,000 dilution; Cell Signaling), rabbit anti-atg5
(1:1,000 dilution; Cell Signaling), goat anti-actin (1:1,000
dilution; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit
anti-MAP2a/b (1:1,000 dilution; Abcam, Cambridge, MA),
rabbit anti-tau (1:1,000 dilution; Cell Signaling), mouse anti-
multiubiquitin (1:500 dilution; Stressgen, Victoria, British Co-
lumbia, Canada), and mouse anti-p62 (1:1,000 dilution;
Abnova, Taipie, Taiwan). Axon growth in compartmental
cultures can be highly variable from chamber to chamber, and
differences in overall protein levels between experiments often
cannot be avoided. Thus, actin immunoblotting was used for
protein normalization between compartments. Actin is known
to be a good marker for the amount of axons and cell bodies
in this culture system, so actin normalization has been adopted
by many investigators who perform immunoblotting on com-
partmentalized cultures. Furthermore, actin accurately reflects
the response of neurons to NGF, a neurotrophic factor that
increases ATP synthesis, protein synthesis and growth, and
indicates the overall increases or decreases in cellular metabo-
lism and axon growth upon manipulation of the trophic status
of the neurons.
Image Analysis and Statistical Analyses
Scanned images of X-ray films were imported into
ImageJ and processed using the gel analysis tool. Integrated
density values obtained from Western analysis were reported
as mean values 6 SEM. Values were normalized to both actin
loading controls reprobed from the same blot and within-blot
(vehicle-treated) controls. In some cases, the immunoblot
images do not exactly match the quantified data. This is due
to inherent variations in the amount of neuronal axons and
cell bodies between individual compartmented chambers,
reflected in the actin controls. Lysosome movement was meas-
ured by using the ImageJ MTrackJ plugin (Erik Meijering,
Erasmus MC—University Medical Center, Rotterdam, The
Netherlands). Equal numbers of lysosomes moving either ret-
rogradely or anterogradely were tracked for at least three
frames, and the average speed was calculated and statistically
compared. Student’s unpaired t-test and one-way ANOVA on
ranks were used as tests of statistical significance where
appropriate. P < 0.05 were considered to be significant. Data
analysis was performed in Sigmaplot with Sigmastat (Systat
Software, Chicago, IL).
RESULTS
Expression and Localization of Protein
Degradation Machinery in Peripheral Neurons
Immunolabeling and immunoblotting with anti-
bodies for MAP2a/b, which is selectively localized in
dendrites, and tau, which is specific for axons, indicated
that the vast majority of neurites produced by sympa-
thetic neurons in vitro were axons (Fig. 1). Furthermore,
MAP2 was absent from the distal axon compartments of
compartmentalized cultures, suggesting that only axons
extend into the side compartments (Fig. 1C,D).
Lysotracker labeling was used to determine the
distribution of lysosomes in the cell bodies, axons, and
terminals of mass cultures of SCG neurons (Fig. 2A,C,E).
Lysosomes were abundant in the cell bodies of SCG neu-
rons and in large caliber axons extending away from the
cell bodies (Fig. 2A) and were also present in the distal
axon and terminal regions of SCG neurons (Fig. 2A,C,E).
Acidic vesicles (lysosomes, late-stage autophagic vesicles)
were observed as either small (<1 lm), single structures or
larger (1 lm) aggregates. It is possible that larger struc-
tures represented autophagic vesicles that had fused with
lysosomes.
Immunocytochemical labeling for proteasome sub-
units revealed that proteasomes were located in both the
cell bodies and the distal axons/terminals of SCG neu-
rons (Fig. 2B,D,F). Proteasome labeling was diffuse and
evenly distributed throughout the cell, as suggested by
the large extent of overlap with phalloidin labeling of
the actin cytoskeleton. Proteasome and actin signals did
not overlap completely, and proteasomes, for example,
were not observed in growth cones (Fig. 2F, arrows).
Immunoblotting of protein extracts collected from
mass cultures of SCG neurons and cell bodies and distal
axons of compartmentalized sympathetic neurons con-
firmed the results from Lysotracker labeling and pro-
vided additional insights into the localization of protein
degradation machinery. Immunoblotting demonstrated
that lysosome (LAMP2), proteasome (PSMA2), and
autophagesome (LC3, ATG5, and beclin-1) markers
were all present in both the distal axons and the cell
bodies of SCG neurons (Fig. 2G). LAMP2 was observed
as a fully glycosylated species (110 kDa) and in hypo-
glycosylated form (<110 kDa). The fully glycosylated
(mature) species was enriched in SCG axons, suggesting
that lysosomal constituents are posttranslationally modi-
fied and assembled in the cell bodies before being trans-
ported to the axons in their mature form. Quantification
of immunoblots revealed that only LAMP2 showed a
significant difference in relative expression level between
SCG cell bodies and terminals, but this was due mostly
to an absence of hypoglycosylated LAMP2 in distal
axons (Fig. 2H). Expression of proteasomes, lysosomes,
and autophagesomes was also observed both in the cell
bodies and in the distal axons of sensory neurons
from the dorsal root ganglion and spinal motor neurons,
indicating that these data may be generalized to other
neurons that innervate peripheral structures, not just
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sympathetic neurons (Fig. 2I). These results indicate that
protein degradation pathways are present in the distal
axons of neurons, although they are somewhat less abun-
dant than in the cell bodies.
NGF Regulates the Expression of
the Proteolytic Machinery
NGF is a target-derived neurotrophic factor that is
required for axon growth and target-mediated survival
during development as well as maintenance of adult neu-
rons (Sofroniew et al., 2001; Ernsberger, 2009). Because
protein degradation facilitates these processes, we
hypothesized that NGF-dependent growth and mainte-
nance are linked to NGF-dependent regulation of the
proteolytic machinery. After 48 hr of NGF withdrawal,
NGF was reintroduced to the distal axons of sympathetic
neurons, and protein extracts were collected either 4 or
48 hr later from both the cell bodies and the distal axons
(Fig. 3A,B). Immunoblots were performed using protein
extracts collected from neurons given medium alone,
stimulated with NGF for 4 hr, or stimulated with NGF
for 48 hr (Fig. 3). The expression levels of both LAMP2
and PSMA2 increased in the distal axons after NGF
stimulation. LAMP2 expression was significantly
increased in the distal axons compared with the cell
bodies after 48 hr of NGF treatment (Fig. 3C). After 48
hr of NGF stimulation, LAMP2 expression was also sig-
nificantly higher in the distal axons than after 4 hr of
NGF stimulation. PSMA2 expression was not signifi-
cantly different after 4 hr of stimulation but increased
significantly in the distal axons after 48 hr NGF applica-
tion (Fig. 3D). PSMA2 and LAMP2 increased by more
than fourfold compared with distal axons treated with
medium alone. In contrast, no significant differences in
LC3 expression were observed among any of the condi-
tions (Fig. 3E). LC3 was observed in two isoforms in
SCG neurons; the larger, 16-kDa isoform represents the
senescent LC3-I form and the smaller, 14-kDa isoform
represents the cleaved (active) LC3-II isoform (Klionsky
et al., 2008). LC3 cleavage indicates membrane fusion
events that cause the formation of a fully functional
autophagic vesicle. Although no significant differences in
LC3 expression were observed upon NGF stimulation,
the ratio of LC3-II/LC3-I suggested that autophagy
occurred more frequently in cell bodies than in the distal
axons of SCG neurons (data not shown). In summary,
these results suggest that NGF regulates the axonal
expression of proteins associated with lysosomes and
proteasomes but does not regulate proteins required for
autophagy.
Differential Sensitivity of Sympathetic Neurons
to Inhibition of Degradation Pathways
Because NGF, a potent growth and survival factor
for SCG neurons, upregulated the expression of proteins
required for proteasomal and lysosomal degradation, we
investigated how sensitive these neurons would be to
inhibition of these protein degradation pathways. Neurons
Fig. 1. Axons are present exclusively in the side compartments of
compartmentalized cultures. A,B: Immunofluorescence revealed that
dendrites (MAP2-positive structures) were less abundant than axons
and extended only a short distance from somas. C: Immunoblotting
of lysates from cell bodies and distal axons revealed that MAP2 protein
was not present in the distal axon compartment, in contrast to tau,
which was highly enriched in distal axons, relative to actin. D: The
relative abundance of MAP2 protein declined over time in culture.
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Fig. 2. Lysosomes, proteasomes, and autophagesomes are expressed
in both the cell bodies and the axons of peripheral neurons. Lyso-
tracker was used to identify lysosomes (green punctuate structures) in
the cell bodies (A; encircled), the axons (C), and the terminals/
growth cones (E) of SCG neurons. Immunofluorescence was used to
determine the localization of proteasomes (green) in the cell bodies
(B), the axons (D), and the terminals/growth cones (F). Phalloidin
was used as a counterstain to label F-actin (red; arrows). G: Immu-
noblots for protein extracts obtained from SCG mass cultures (SCG
MC), compartmented SCG cell bodies (SCG CB), and compart-
mented SCG distal axons (SCG DA) confirmed that LAMP2,
PSMA2, and three markers for autophagic vesicles (LC3, ATG5, and
beclin-1) were expressed in both peripheral nerve tissue and all parts
of primary sympathetic neurons. H: Differences in relative expression
level of proteolytic machinery were observed between cell bodies
and distal axons (P < 0.01 by Student’s unpaired t-test). I: Dorsal
root ganglion (DRG) neurons and spinal motor (SM) neurons
express PSMA2, LAMP2, and LC3 in both the cell bodies and the
distal axons. These data suggest that some results from SCG cultures
may be generalized to other neuronal cell types that innervate
peripheral targets. Scale bars 5 10 lm in A (applies to A,C,E);
100 lm in B (applies to B,D,F).
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Fig. 3. NGF regulates lysosomes and proteasomes but not autophage-
somes. A: SCG neurons were cultured for 21 days, deprived of NGF for
48 hr, and then reintroduced to NGF before protein extracts were col-
lected from both the cell bodies (CB) and distal axons (DA). B: Repre-
sentative immunoblots are shown for LAMP2, PSMA2, and LC3 in
SCG neurons stimulated on the distal axons with medium without NGF
for 4 hr (2NGF CB, DA), 50 ng/ml NGF for 4 hr (NGF 4 CB, DA),
and 50 ng/ml NGF for 48 hr (NGF 48 CB, DA). C–E: Measurements
from NGF-treated samples were normalized to the 2NGF controls and
actin and statistically compared (one-way ANOVA on ranks).
C: LAMP2 expression in the distal axons was significantly higher after
48 hr of NGF treatment compared with both the cell bodies at 48 hr
and the terminals at 4 hr. D: PSMA2 expression increased significantly
in the distal axons compared with the cell bodies after 48 hr of NGF
treatment. E: No significant differences were measured between NGF
treatment conditions for LC3. P < 0.05 was considered significant.
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were exposed to one of three inhibitors of protein degra-
dation, concanamycin, epoxomicin, and 3-MeA, which
inhibit lysosomes, proteasomes, and autophagosomes,
respectively. The toxic effects of these and other agents are
typically obvious in SCG cultures, and are manifested as
changes in structure of the cell soma and axonal network.
Sympathetic neurons exposed to the vehicle alone
(DMSO) did not undergo degeneration or cell death
over 96 hr (Fig. 4). When neurons were exposed to
epoxomicin, no acute effects were observed. As
expected, the sustained inhibition of proteasomes (96 hr)
caused neurite degeneration and cell death, as evidenced
by detachment of cell bodies and partial disintegration
of processes that remained attached to the substrate
(Fig. 4D–F). When neurons were given concanamycin
A, cell death also occurred within 96 hr (Fig. 4G–I).
However, we observed that neurons were capable of
surviving short periods of inhibition (24–48 hr). Inhibi-
tion of autophagy using 3-MeA did not result in death
of SCG neurons even after 96 hr of exposure (Fig. 4J–
L). In fact, no discernible differences in cell morphology
were observed between 3-MeA-treated neurons and
Fig. 4. Differential sensitivity of sympathetic neurons to proteasome,
lysosome, and autophagy inhibitors. Mass cultures of SCG neurons
treated with vehicle control (A–C), epoxomicin (D–F), concanamycin
A (G–I), or 3-methyl-adenine (J–L) were observed over the course of
96 hr. SCG morphology was unaffected upon exposure to 3-methyl-
adenine for over 96 hr. Application of proteasome or lysosome inhibi-
tors (epoxomicin and concanamycin A respectively), in contrast,
resulted in death of SCG neurons over the course of several days, as
indicated by the detachment of cell somas and presence of granulated
and degenerating neuronal processes. Scale bars5 100 lm.
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neurons given the vehicle alone, suggesting that autoph-
agy was not necessary for the survival of sympathetic
neurons maintained in nutrient-rich conditions over a
period of 4 days. We chose, based on these observations,
treatment time points within the acute (24 hr, low tox-
icity) period to minimize any toxic effects in subsequent
experiments.
Inhibition of Proteasomes in Axons Causes the
Local Accumulation of Ubiquitinated Proteins
It has been proposed that one cause of neurodegen-
eration is the accumulation of toxic or misfolded proteins
in the axons of neurons (Taylor et al., 2002). We
hypothesized that acute inhibition of the proteolytic path-
ways in either the cell bodies or the distal axons of SCG
neurons would result in the accumulation of ubiquitinated
proteins in these compartments. A treatment period of 24
hr was chosen based on the observations that neuronal
morphology was unaffected after the acute treatment with
either epoxomicin or concanamycin A (Fig. 4E,H).
Representative immunoblots of sympathetic neu-
rons maintained in compartmentalized cultures that were
given epoxomicin on either the cell bodies or distal
axons are shown in Figure 5A–C. Levels of the protea-
some component PSMA2 were measured to determine
whether perturbations in protein flux through the pro-
teasome had an effect on the level of proteasome expres-
sion (Korolchuk et al., 2010). PSMA2 expression
increased in the distal axons in response to proteasome
inhibition on the terminals (Fig. 5D). Ubiquitinated pro-
teins increased in the SCG terminals after epoxomicin
had been applied to the terminals (Fig. 5E,F). An accu-
mulation of multiubiquitinated proteins destined for the
proteasome was also observed in the cell bodies after
proteasomal degradation had been selectively inhibited
on the cell bodies. Interestingly, similar trends were
observed for multiubiquitinated proteins and total ubiq-
uitin (both proteasome and lysosome), which accumu-
lated in axons when proteasomes had been inhibited in
axons (Fig. 5F). These data suggest that proteasome inhi-
bition results in the local accumulation of proteins tar-
geted for proteasome degradation and that compensatory
mechanisms, such as retrograde transport of ubiquitinated
proteins to another cellular compartment, do not aid in
degradation after acute proteasome inhibition.
Inhibition of Lysosomal Degradation in Axons
Does Not Cause Local Protein Accumulation
We selectively inhibited lysosomes in either the
cell bodies or the distal axons of SCG neurons to deter-
mine whether deficiencies in lysosomal degradation
in axons result in the accumulation of ubiquitinated
Fig. 5. Localized inhibition of proteasomes results in the accumula-
tion of ubiquitinated proteins in compartmentalized neuronal cul-
tures. A–C: Representative Western blots for PSMA2 (proteasomes),
multiubiquitin, and total ubiquitin. D: Inhibition of proteasome
function in distal axons (E-DA) or cell bodies (E-CB) resulted in
increases in PSMA2 expression. E,F: Ubiquitinated proteins accu-
mulated in the axons/terminals following proteasome inhibition in
the terminals. A modest accumulation of ubiquitinated proteins also
occurred in the cell bodies after proteasome inhibition in the cell
bodies. Values were normalized to actin and an in-blot vehicle-
treated control and displayed as mean 6 SEM.
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proteins. LAMP2 expression was significantly higher in
the cell bodies of SCG neurons compared with the distal
axons when lysosomes were inhibited in the cell body
compartment. Likewise, LAMP2 expression was induced
significantly in the distal axons compared with the cell
bodies when lysosomes were inhibited in the terminal
compartments (Fig. 6A,B). These data suggest that either
more LAMP2 protein is synthesized or that lysosomes
are selectively transported in response to a decrease in
lysosomal protein degradation to the cellular compart-
ment where lysosomes are inhibited. Fully glycosylated
LAMP2 is enriched in axons, so it is likely that lysoso-
Fig. 6. Selective inhibition of lysosomes does not cause the accumu-
lation of proteins in compartmentalized neuronal cultures. Concana-
mycin A was used to inhibit lysosomes selectively in either the
cell body or the distal axon compartments of SCG cultures.
A,B: LAMP2 protein expression was greater in the cell bodies after
inhibition of lysosomes in the cell body compartment. LAMP2
expression was also significantly greater in the distal axons (DA) after
inhibition of lysosomes in the terminal compartment. No significant
accumulation of transferrin receptor (C,D) or total ubiquitin
(E,F) was observed following selective lysosome inhibition on
either the cell bodies or the distal axons. Bars represent mean 6
SEM. P < 0.05 was considered significant (one-way ANOVA on
ranks). Values were normalized to actin and an in-blot vehicle-
treated control.
Axonal Protein Degradation in Neurons 1541
Journal of Neuroscience Research
mal constituents are synthesized in the cell bodies and
trafficked to the axons after assembly.
In contrast to proteasome inhibition, lysosome inhi-
bition did not result in any trends in the local accumula-
tion of proteins. Transferrin receptor, a model receptor
for lysosomal degradation, did not accumulate in response
to local lysosome inhibition (Fig. 6C,D). Importantly, no
significant differences or trends between experiments
were observed for the local accumulation of ubiquitinated
proteins, suggesting that lysosome inhibition in subcellular
regions of neurons does not lead to the local accumula-
tion of proteins targeted for degradation (Fig. 6E,F). In
addition, inhibition of autophagy did not result in local
protein accumulation in either axons or cell bodies, as
indicated by examination of the expression of the ubuiqi-
tin binding adaptor protein p62 and ubiquitinated
proteins (Fig. 7). In summary, the local inhibition of
lysosomes does not cause the regional accumulation of
proteins targeted for lysosome degradation, such as ubiq-
uitinated proteins and the transferrin receptor.
Lysosomes Are Transported Between
Cell Bodies and Axons Via Microtubules
The lack of ubiquitinated protein accumulation
following local lysosome inhibition in axons could be
linked to the transport of lysosomes within axons.
Although lysosomes are capable of moving short distan-
ces along actin filaments and microtubules in nonneuro-
nal cells (Cordonnier et al., 2001), it is not known
whether lysosomes can be transported over long distan-
ces in axons in either a retrograde or a anterograde
direction. To examine the possibility that lysosome
transport prevented the accumulation of ubiquitinated
proteins following lysosome inhibition, we examined the
transport properties of lysosomes within axons.
Tracking lysosomes in living sympathetic neurons
revealed that lysosomes moved considerable distances
along the axons and terminals (Fig. 8A–F). Inspection of
overlaid phase-contrast and lysosome images using the
fluorescent dye Lysotracker demonstrated that acidic
vesicles moved retrogradely from the distal axons of
SCG neurons (Griffiths et al., 1988). Two populations
of lysosomes were observed in neurons: some lysosomes
moved anterogradely toward the terminals, whereas
other lysosomes moved retrogradely away from the ter-
minals toward the cell bodies. Lysosomes segregated into
two groups based on the direction and speed of their
movement (Fig. 8G). Lysosomes moving retrogradely
progressed shorter distances over a given time than those
moving anterogradely. These data were used to compute
the average instantaneous velocity of movement for lyso-
somes moving anterogradely and for those moving retro-
gradely. Lysosomes moving anterogradely within axons
travelled at an average velocity of 1.2 lm/sec (Fig. 8H).
Based on their speed and relatively continuous rate of
movement, it is likely that such lysosomes were trans-
ported along microtubules by kinesins. The population
of lysosomes moving retrogradely travelled at a slower
rate (0.46 lm/sec) and moved discontinuously, indicat-
ing that they were transported along microtubules by
dyneins (Fig. 8H).
Fig. 7. Inhibition of autophagy does not result in a significant accumu-
lation of degradation products. No significance differences between
treatment conditions or trends among experiments were observed for
LC3 (A), the ubiquitin adaptor protein p62 (B), or total ubiquitin (C) in
response to treatment with the autophagy inhibitor 3-methyl-adenine
(3MA). Significance was tested by one-way ANOVA on ranks.
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Fig. 8. Lysosomes move retrogradely and anterogradely within the
axons of sympathetic neurons. Lysosome movement was tracked in
the axons of SCG neurons to assess the impact of lysosome translo-
cation on axonal protein degradation. A–F: Lysosomes were
observed to move bidirectionally in the terminals of SCG axons.
Arrows indicate the retrograde movement of a single lysosome over
the course of 12 sec. G: Movement profiles for individual lyso-
somes were color-coded based on the direction of movement (red
for anterograde and cyan for retrograde). Lysosomes segregated into
two populations based on their movement profiles. H,I: Average
velocity was plotted for all lysosomes, those moving anterogradely
and those moving retrogradely. Average velocity was also measured
in the presence of nocodazole. Thick dashed lines represent the
mean. Solid lines within the boxes represent the median with first
(top and bottom of box) and second (whisker bar) standard devia-
tions. Gray circles represent individual data points. P < 0.05
was considered to be significant (Student’s unpaired t-test). Scale
bars 5 10 lm.
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As expected from these above, lysosome movement
was abolished by destabilizing microtubules with noco-
dozole (Fig. 8I). In the absence of nocodazole, lysosomes
moved at an average rate of 0.8 lm/sec. After 30 min of
nocodazole treatment, the average velocity of lysosomes
was reduced to 0.2 lm/sec. Residual movement was
due primarily to Brownian-type motion within the cell,
demonstrating that lysosomes depend completely on
microtubule transport to move between cell bodies and
terminals.
DISCUSSION
Our results indicate that protein degradation is per-
vasive within the axons of peripheral neurons. Proteins
associated with all three protein degradation pathways
(proteasomal, lysosomal, and autophagic) were present in
both the axons and the cell bodies of sympathetic neu-
rons. These proteins were also present in vitro within
the axons of DRG sensory neurons and spinal motor
neurons, suggesting that axonal protein degradation is a
general property shared among peripheral neurons. The
levels of proteins associated with proteasome and lyso-
some degradation were upregulated in response to NGF
treatment, linking the processes of axon growth and
maintenance to protein degradation. The inhibition of
proteasome activity selectively in axons resulted in local
accumulation of ubiquitinated proteins in axons. In con-
trast, inhibition of lysosome activity in axons did not
result in accumulation of either transmembrane receptors
typically degraded by lysosomes, such as the transferrin
receptor, or ubiquitinated proteins, indicating a potential
role of lysosome translocation in protein degradation.
Interestingly, retrograde and anterograde lysosome
movements were observed in the axons of sympathetic
neurons, which were both disrupted upon the destabili-
zation of microtubules with nocodazole. This raises the
possibility that subcellular lysosomal inhibition does not
cause the accumulation of ubiquitinated proteins because
of the transport of lysosomes to other cellular regions.
Localization of Protein Degradation
Machinery in Axons
The role of protein degradation in neuronal func-
tion and maintenance has been appreciated primarily in
the context of protein turnover within cell somas and
dendrites (Colledge et al., 2003; Goldberg, 2003; Ara-
ncibia-Carcamo et al., 2009). Proteasome degradation
has been linked to a number of dynamic processes that
occur within dendrites, most notably dendrite morpho-
genesis, as well as activity-dependent plasticity and long-
term potentiation (Ehlers, 2003; DiAntonio and Hicke,
2004). In dendrites, proteasome function is closely linked
to synaptic activity. This phenomenon has been illus-
trated by the recruitment and enrichment of proteasomes
into dendritic spines (Bingol and Schuman, 2006).
Lysosomal degradation has also been appreciated in the
contexts of neurite remodeling as well as turnover of
receptor/complexes at postsynaptic structures (Luzio
et al., 2007; Song et al., 2008). Alterations in protein
degradation by lysosomes and proteasomes have been
linked to protein accumulation disorders and degenera-
tion/regeneration of axons (Rubinsztein, 2006). Although
it is likely that some protein degradation occurs following
retrograde translocation of endosomal vesicles to cell
bodies, the abundance of lysosomes, proteasomes, and
autophagic proteins within distal axons suggests that local
axonal protein degradation contributes to proteome
homeostasis within axons. The accumulation of ubiquiti-
nated proteins in axons upon local proteasome inhibition,
along with the anterograde and retrograde transport of
mature lysosomes, further supports this notion.
NGF and Regulation of Protein Degradation
NGF supports the target-dependent survival,
growth, and maintenance of sympathetic and sensory neu-
rons (Sofroniew et al., 2001; Ernsberger, 2009). Our ob-
servation that proteasome- and lysosome-associated pro-
tein levels were upregulated by NGF selectively in axons
suggests that axonal protein turnover is necessary for axo-
nal growth and maintenance. Therefore, a loss of trophic
factor support may contribute to degenerative disorders
associated with protein accumulation in axons, such as
Alzheimer’s and Parkinson’s diseases, by exacerbating the
accumulation of misfolded and/or ubiquitinated proteins
(Hennigan et al., 2007). It will be important in future
studies to determine the precise function that the NGF-
induced increase in protein degradation has in axons,
especially because levels of NGF in target tissues often
decline after development and during adulthood. Impor-
tantly, the increase in proteasomal and lysosomal proteins
in axons in response to NGF was greater than the increase
in actin, which is a faithful marker of the trophic effects of
NGF on global protein levels.
The levels of both PSMA2 and LAMP2 increased
selectively in the axons of NGF-stimulated neurons at
48 hr. The levels of LC3 did not increase in axons fol-
lowing NGF stimulation, thus serving as an important
control (in addition to actin) that suggests that NGF
selectively upregulates proteins associated with protea-
somes and lysosomes in axons. It is important to note
that autophagy is active in NGF-maintained axons, as
evidenced by the appearance of the active form of LC3
(LC3-II) in axonal lysates. This demonstrates that the
lack of evidence for NGF regulation of autophagy is not
due simply to an absence of active autophagy in these
axons. Overall, these data suggest that an augmentation
of protein degradation is necessary for some specific as-
pect of NGF-mediated axon growth or maintenance,
rather than simply being necessary as a housekeeping
function for axon homeostasis.
Transport Properties of Protein
Degradation Machinery
The cell bodies and terminals of most neurons are
often separated by large distances, requiring the transport
of mRNA, protein components, and complete protein
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complexes/organelles for the maintenance of functional
axons and terminals. By inhibiting the function of pro-
teolytic machinery within either cell bodies or axons it
was possible to understand how transport properties can
affect the flux of proteins through degradation machin-
ery. Inhibition of proteasome function resulted in the
accumulation of ubiquitinated proteins in the inhibited
compartment, suggesting that the ubiquitin-proteasome
system (UPS) lacks mechanisms for transport of ubiqui-
tinated proteins out of the inhibited compartment. This
supports previous reports indicating that local degrada-
tion is particularly important in the UPS (DiAntonio
and Hicke, 2004; Bingol and Schuman, 2006). Indeed,
proteasomes have been observed to aggregate in regions
of high protein turnover. In contrast, protein accumu-
lation was not observed following lysosome inhibition.
However, an increase in lysosome-associated protein
expression was observed in the inhibited compartments,
suggesting either that lysosome expression was upregu-
lated or that lysosome translocation occurred in
response to a decrease in local protein degradation. The
lack of protein accumulation in concanamycin A-inhib-
ited compartments likely is due to the transport of
endosomes or lysosomes out of the inhibited compart-
ment to a region of the neuron where degradation
could occur.
Lysosomes were observed to move great distances
both anterogradely and retrogradely within neurons,
consistent with some previous studies (Overly et al.,
1996). These data support a model in which lysosomal
cargo can be either degraded in axons or transported
between axons and cell bodies for degradation. During
intracellular transport, lysosomes can move bidirection-
ally and undergo fusion events with endosomes and
autophagesomes, thus providing a dynamic and locally
tuned mechanism for protein degradation to accompany
the stable local degradation of the UPS. It is likely that
autophagy is also occurring in axons given the presence
of fully mature autophagosomes. Even so, some studies
have demonstrated that lysosomes function independ-
ently of autophagosomes to degrade transmembrane
proteins. For example, most plasma membrane-located
receptors are trafficked to lysosomes for degradation,
and this process does not involve autophagy. Rather,
autophagy is involved primarily in the degradation of
organelles and large cellular structures, often as a
response to nutrient deprivation. The observation that
lysosomes can move within neurons to overcome defi-
ciencies in local degradation has implications for neuro-
degenerative diseases, raising the possibility that diseases
affecting axonal transport mechanisms may impede the
adaptive ability of the neuron to remove ubiquitinated
proteins that are accumulating in axons due to the dis-
ease process, thereby impacting the synaptic function of
the neuron. It is thus possible that the apparent toxicity
of some protein inclusion structures, such as those
related to Ab and tau, is caused in part by deficiencies
in the transport of protein degradation machinery
within axons.
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